StockTwits, founded in 2008 by Howard Lindzon and Soren Macbeth, is a leading social media platform designed specifically for investors and traders to share real-time market insights, ideas, and strategies. Headquartered in New York City, the company pioneered the use of "cashtags" (e.g., $AAPL) to organize financial discussions, initially integrating with Twitter before evolving into a standalone network.
The company shared Phase 1 trial results for CX-2051, an antibody-drug conjugate for advanced colorectal cancer, with 28% of patients achieving confirmed partial responses.
Tariff news flow, first-tier economic data, and a few earnings reports could decide the day's trading direction, although the momentum is decisively in favor of further gains.
Invivyd unveiled a discovery program for a measles-targeted monoclonal antibody, responding to provider demand amid a lack of approved treatments or post-exposure options.
JPMorgan analysts said President Trump’s "most favored nation" drug pricing order is unlikely to move forward without Congressional support and will likely face legal and industry resistance, limiting its near-term impact on pharma stocks.
Despite a sharp decline in stock price, retail traders are optimistic about the company's potential, citing its core asset Rencofilstat and speculating on a rebound following the OTC transition.
CEO Larry Coben said the transaction is financially compelling as it strengthens the company’s credit profile, boosts its growth rate, and supports continued robust capital returns.
KindlyMD CEO Tim Pickett said the merger allows the company to preserve and expand its mission to combat opioid dependency through alternative medicine while gaining a new engine for shareholder value creation.
The U.S. President said that Big Pharma would either voluntarily abide by this principle or the federal government will use its power to ensure the U.S. pays the same price as other countries.
U.S. Treasury Secretary Scott Bessent cited the need to protect the semiconductor, steel, and pharmaceutical industries in the negotiations between the two countries.
The company also reiterated its full-year total revenue guidance of $250 million to $260 million and net product sales guidance of $240 million to $250 million.
A ceasefire between India and Pakistan and a breakthrough U.S.-China trade deal sparked a major rally on Dalal Street; IT, metals, and travel stocks led the surge amid broad-based buying.
Analyst Saurabh Sahu believes the stock has the potential to rise to the ₹830 to ₹850 range, while recommending a strict stop-loss at ₹775 to manage the downside risk.
The firm's report echoes the sentiment across the travel and hospitality sector, where demand is strained due to macroeconomic uncertainties and geopolitical unrest.
The Boston-based firm forecasted 2025 adjusted EBITDA between $540 million and $560 million, compared with its earlier projection between $510 million and $530 million.
The railroad operator said the agreement includes general wage increases and health and welfare improvements, similar to its agreements with 13 other unions.
This would mean the combined 145% tariffs on Chinese imports will be reduced to 10% by May 14, while the 20% duties related to fentanyl will stay in place.
Trump’s Most Favored Nation (MFN) drug pricing policy could significantly compress margins, disrupt product pipelines, and force Indian firms to rework their U.S. strategies.
Dr. Reddy’s shares are approaching a key resistance zone following a strong Q4FY25 earnings beat, according to Balakkala. A breakout above this level could trigger a rally toward ₹1,260 and ₹1,400.
For the week ending May 9, 2025, three small- and mid-cap auto stocks experienced notable increases in Stocktwits follower counts, reflecting heightened retail investor interest.
Despite declines in stock prices for some, such as UCO Bank and Punjab & Sind Bank, analysts see growth potential in these companies, driven by digital initiatives, strategic lending, and expansion plans.
After announcing a 24% tariff on Japanese imports in early April as part of President Donald Trump’s Liberation Day levies, the U.S. has paused implementation to allow scope for negotiations.
A strategist said that until further signs of a weakening economy, the Fed will remain on the sidelines, given the first-quarter contraction was primarily due to the tariff-related hit to net exports.
Eli Lilly’s Zepbound led to 47% greater weight loss than Wegovy in a 72-week trial, yet retail sentiment turned bearish on Stocktwits amid heightened scrutiny on drug pricing following Trump’s vow to slash U.S. prescription costs by up to 80%.
The proposal, citing a "Most Favored Nation Policy," fueled debate prompted some watchers to question the legality and feasibility of the move, while others speculated on its potential market impact.
U.S. Trade Representative Jamieson Greer stated that the speed with which the U.S. and China could reach an agreement showed that perhaps the differences were not as large as initially thought.
Short interest in Hims & Hers rose to a record high of 37%, continuing a four-week climb, even as the stock surged 42% last week. The company’s quarterly revenue more than doubled, surpassing analyst expectations.
Despite soaring short interest, retail sentiment remains bullish, with investors optimistic about the company’s positive trial results and the continued demand for its FDA-approved treatment, Rezdiffra.
